Antonia Chen, MD/MBA

Antonia F. Chen MD/MBA is the Chair of the Department of Orthopaedics at University of Texas Southwestern. She is a Professor of Orthopaedic Surgery with tenure and holds the Charles F. Gregory Distinguished Chair in Orthopaedic Surgery. She was an Associate Professor at Harvard Medical School and the Chief of Arthroplasty and Joint Reconstruction at Brigham and Women’s Hospital. She held the Michael A. Bell Family Distinguished Chair in Healthcare Innovation. She was previously the Director of Arthroplasty Research at Brigham and Women’s Hospital, and she was also the Associate Director of Research at the Rothman Institute in Philadelphia, an Associate Professor at Sidney Kimmel Medical College, and the Director of Medical Education Curriculum, Musculoskeletal Studies at the Sidney Kimmel Medical College and Thomas Jefferson University. She received her BS from Yale University and her MD from Rutgers Medical School, where she graduated with Distinction in Research and was inducted into the Alpha Omega Alpha Medical Honor Society. Antonia received her MBA from Rutgers Business School and is a member of the Beta Gamma Sigma Honor Society. She completed her orthopaedic residency at the University of Pittsburgh and her fellowship in hip and knee arthroplasty at the Rothman Institute. She is a member of the Knee Society, and the first female surgeon in the Hip Society. She is on the editorial board of 8 journals, and was president of the Musculoskeletal Infection Society. She is currently in the presidential line of the American Association of Hip and Knee Surgeons. She has authored over 425 publications, 45 book chapters, and 4 books, has won multiple research and mentoring awards, and has presented all over the world.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:StrykerTopic:Implant company consultantDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AvanosTopic:Radiofrequency ablationDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BICMDTopic:Patient careDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ConvatecTopic:Wound careDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:EthiconTopic:Infection preventionDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:HeraeusTopic:CementDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:IrriMaxTopic:Infection prevention and treatmentDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Stock OptionsIneligible company:Osteal TherapeuticsTopic:Infection treatmentDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PeptilogicsTopic:Infection treatmentDate added:03/31/2025Date updated:03/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SolenicTopic:Infection prevention and treatmentDate added:03/31/2025Date updated:03/31/2025
Pages
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.

Facebook
X
LinkedIn
Forward